COPD and Cardiovascular Risk: The Expanding Role of Biomarkers

Chronic obstructive pulmonary disease (COPD) has long been recognized as a progressive respiratory condition characterized by airflow limitation and chronic inflammation. Increasingly, however, clinicians are recognizing that its impact extends well beyond the lungs.

Cardiovascular disease (CVD)—including ischemic heart disease, heart failure, pulmonary hypertension, and arrhythmias—accounts for a substantial share of morbidity and mortality in COPD. Patients with COPD are estimated to be 2 to 5 times more likely to develop cardiovascular disease, and in many cases, cardiovascular complications ultimately surpass respiratory failure as the leading cause of death.

This growing awareness is reshaping our approach to COPD management. Rather than treating pulmonary symptoms in isolation, attention is shifting towards the systemic processes that link COPD with cardiovascular risk. Particularly, biomarkers are emerging as valuable tools for identifying patients who may be vulnerable to cardiovascular complications earlier in the disease course. A recent review by Valizadeh and colleagues published in the Journal of Clinical Medicine explores this evolving landscape.

Shared Pathways Driving Dual Disease
The connection between COPD and cardiovascular disease cannot be explained by shared risk factors alone. While smoking, aging, and environmental exposures contribute to both conditions, COPD itself appears to promote cardiovascular pathology through several interconnected biological mechanisms.

Systemic inflammation is a central feature. Persistent exposure to inhaled irritants—such as cigarette smoke or environmental pollutants—triggers chronic inflammatory activity in the airways. Over time, inflammatory mediators including cytokines and chemokines, enter systemic circulation, contributing to endothelial dysfunction and accelerating atherosclerosis. Elevated markers such as interleukin-6, C-reactive protein (CRP), and intercellular adhesion molecule-1 (ICAM-1) have been linked to both declining lung function and increased cardiovascular risk.

Oxidative stress further amplifies vascular injury. Excess reactive oxygen species reduce nitric oxide bioavailability, impairing endothelial function and promoting arterial stiffness—both key contributors to cardiovascular disease. Hypoxia, commonly seen in advanced COPD due to ventilation-perfusion mismatch, also intensifies systemic inflammation and can drive vascular remodeling.

Mechanical factors play a role as well. Lung hyperinflation—an often-overlooked consequence of COPD—raises intrathoracic pressure and reduces venous return to the heart. Over time, these hemodynamic changes can increase right ventricular strain and disrupt overall cardiac performance. Together, these processes create a physiologic environment in which pulmonary disease and cardiovascular pathology reinforce each another.

Biomarkers at the Intersection of Lung and Heart Health
Within this complex pathophysiologic framework, circulating biomarkers are attracting growing interest as tools for identifying COPD patients at elevated cardiovascular risk.

Traditional inflammatory markers remain clinically relevant. Elevated CRP levels have been associated with reduced lung function and a higher likelihood of ischemic heart disease, while fibrinogen—an acute-phase reactant involved in coagulation—has been linked to both COPD exacerbations and thrombotic cardiovascular events.

Cardiac biomarkers also provide important insights. B-type natriuretic peptide (BNP) and its precursor NT-proBNP, which are released in response to ventricular stretch, are widely used in heart failure diagnosis. In COPD patients, elevated levels may signal right ventricular dysfunction, pulmonary hypertension, or cor pulmonale. Similarly, high-sensitivity cardiac troponin has been associated with myocardial injury and increased mortality risk during COPD exacerbations.

Beyond these established markers, several emerging biomarkers are under investigation. Growth differentiation factor-15 (GDF-15), a marker of cellular stress, has been associated with worsening lung function, increased exacerbation frequency, and higher mortality risk. Galectin-3, which plays a role in myocardial fibrosis and remodeling, may help identify patients with evolving cardiac dysfunction. Other candidates—including soluble urokinase plasminogen activator receptor (suPAR), surfactant protein-D, and neopterin—reflect broader inflammatory and immune pathways that intersect with vascular disease.

Although many of these biomarkers remain primarily within the research domain, their combined use may eventually enable more precise cardiovascular risk stratification in patients with COPD.

Toward Biomarker-Guided Precision Care
The expanding biomarker landscape highlights an important clinical message: COPD should be viewed not just as a pulmonary disorder, but as a systemic disease with significant cardiovascular implications. Biomarkers may help clinicians detect early cardiovascular stress, distinguish cardiac events from pulmonary exacerbations, and identify patients who could benefit from targeted therapies.

Therapeutic strategies are increasingly reflecting this integrated perspective. Inhaled triple therapy—including corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonists—has demonstrated reductions in exacerbation rates and mortality in COPD populations. Anti-inflammatory treatments, like phosphodiesterase-4 inhibitors, may also help reduce exacerbations by modulating inflammatory pathways. Meanwhile, statin therapy has shown promise in lowering systemic inflammation and improving cardiovascular outcomes in COPD patients with elevated inflammatory markers.

The intersection of COPD and cardiovascular disease represents an important frontier in chronic disease management. Biomarker-guided strategies may offer a pathway toward earlier detection of cardiovascular risk, more individualized treatment decisions, and improved long-term outcomes.

As research continues to evolve, future approaches may rely on integrated biomarker panels rather than single laboratory markers to identify high-risk patients. This shift toward precision medicine reflects a broader understanding that COPD is part of a complex systemic disease network—one that requires coordinated, multidisciplinary care spanning pulmonary and cardiovascular medicine.

Reference
Valizadeh M, Jensen JU, Ceasovschih A, Corlateanu A, Sivapalan P. COPD and cardiovascular diseases: biomarker-guided stratification and therapeutic perspectives. J Clin Med. 2026;15(1):49. doi:10.3390/jcm15010049.